AstraZeneca: inconclusive trial for Infinzi in NSCL
We are disappointed by the results of the trial. Imfinzi has helped to change the therapeutic landscape and has achieved several positive results in Phase III trials for patients with earlier-stage lung cancer', commented Susan Galbraith, Executive Vice President, Oncology R&D at AstraZeneca.
'We remain committed to addressing unmet needs in lung cancer through our extensive development program', she added.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction